Madrigal Pharmaceuticals, Inc. (MDGL) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in West Conshohocken, PA, United States. The current CEO is William J. Sibold.
MDGL has IPO date of 2007-02-06, 528 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $12.04B.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing innovative therapeutic candidates for cardiovascular, metabolic, and liver diseases. The company's lead product, resmetirom, is a liver-directed selective thyroid hormone receptor-ß agonist currently in Phase III clinical trials for treating non-alcoholic steatohepatitis. Madrigal is also advancing MGL-3745 as a backup compound and has established a research, development, and commercialization partnership with Hoffmann-La Roche. Headquartered in West Conshohocken, Pennsylvania, the company is positioned to address significant unmet medical needs in serious metabolic and hepatic diseases.
